Kathy What Is the Risk of Low HDL-C?
|
|
- Tamsyn Walsh
- 6 years ago
- Views:
Transcription
1 Targeting Better Cardiac Outcomes for High Risk Patients Daniel Soffer, MD, FNLA Clinical Associate Professor of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA Learning Objectives Evaluate recent clinical trials with respect to management of low HDL-C Examine the data on triglycerides and CVD risk to determine how aggressively to treat patients with elevated TGs Employ strategies for reducing CVD risk in patients with type 2 diabetes and hypertension Case 1: Kathy, 45 y/o female Pre-op consult for elective cholecystectomy Only complaint is intermittent RUQ pain Borderline HTN ; weight loss was recommended Habits/SH: Nonsmoker, social alcohol, intermittent exercise program, middle school teacher FHx: Father, CAD and MI age 65; Mother, DM PE: mean BP 138/86; BMI=30 Blood work (mg/dl): TC 200, HDL-C 36, LDL-C 124, TG 190; nonhdl-c 164 Glucose 102; remainder unremarkable No meds Is Kathy at Risk? Low risk (only 1 major risk factor) Framingham risk score (to be calculated if >2 RF s) = 1% Pooled cohort equation, 1.6% 10-yr risk, 39% lifetime risk Kathy What Is the Risk of Low HDL-C? What are her associated risks? Borderline elevated blood pressure ( 130/85) Low HDL-C (<50 mg/dl) Obesity (waist circumference >35 in?) Elevated triglycerides ( 150 mg/dl) Borderline fasting glucose The Framingham Heart Study demonstrated a strong inverse relationship between HDL-C and CHD It is estimated that for every increase in HDL-C by 1 mg/dl there is a 2% lower risk of CHD for men and 3% lower risk for women This patient has at least 3 or 4/5 criteria for the metabolic syndrome Gordon DJ, et al. Circulation. 1989;79:8-15. Third Report of the NCEP Expert Panel. JAMA. 2001;285:
2 Low HDL-c Is an Independent Predictor of CHD Risk Even When LDL-C Is Low [lumen] MCP, VCAM endothelium RCT glycoprotein matrix TNFα, IL-6 B CHD Risk A1 Ox LDL-C (mg/dl) HDL-C 85 (mg/dl) Antioxidant Antiinflammatory Antithrombotic MMP, elastase Gordon T, et al. Am J Med. 1977;62: Steinberg D: Atheroscler Rev 1988, 18:1-23. Is Low HDL-C Simply a Marker of Increased Cardiovascular Risk? Low HDL-C levels common in Smokers Sedentary Obese Insulin resistant or diabetic High TG Chronic inflammatory diseases Isolated low HDL-C uncommon and not always harmful Marker for high apolipoprotein B (nonhdl-c, small dense LDL, high LDLp) HDL and apoai are directly atheroprotective Rader DJ and Tall AR. Nature Medicine. 2012;18: Prevalence of Low HDL Varies geographically/ethnically United States: 31% in men, 12% in women United States: 35% in Hispanic men United Kingdom: 23% in men, 8% in women China: 8% in men, 2% in women Low HDL-C is commonly associated with other risk factors: Cardiometabolic Risk Carroll MD, et al. Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, NCHS data brief, no. 92.; Bruckert E. Eur Heart J Suppl. 2006;8 (suppl F): F17-F22. Guidelines Define Low HDL-C as CV Risk Factor NCEP ATP III: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Implications of Recent Clinical Trials for the NCEP ATP III Guidelines (2004) ADA/ACCF Consensus statement on Lipoprotein Management in Patients with Cardiometabolic Risk (2008) 2013 ACC/AHA Cholesterol Guidelines NCEP ATP III (2001) and 2004 Update Treatment of low HDL-C (<40 mg/dl) First reach LDL-c goal, then: Intensify weight management and physical activity If triglycerides mg/dl, achieve nonhdl-c goal In a high risk person with high TG or low HDL-C combining a fibrate or nicotinic acid with an LDL lowering drug can be considered NonHDL-C = TC HDL-C Third Report of the NCEP Expert Panel. JAMA. 2001;285: ; Grundy, et al. Circulation. 2004;110: ; ADA/ACCE Consensus. Brunzell JD, et al. JACC. 2008;51: Third Report of the NCEP Expert Panel. JAMA. 2001;285: ; Grundy, et al. Circulation. 2004;110:
3 Non-HDL-C Triglyceride Cholesterol All atherogenic lipoproteins HDL LDL IDL VLDL Chylomicron remnant 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines APO A 1 APO B APO B APO B APO B 48 non HDL Circulation; November 2013 nonhdl C= Total cholesterol HDL C Figure courtesy of Michael Davidson, MD Recent Trials Addressing Treatment of Low HDL-C Niacin: The Coronary Drug Project Niacin AIM-HIGH (no benefit when LDL-C at target) HPS-2 THRIVE (no benefit, higher risk of myopathy) CETP inhibitors Torcetrapib (harm), dalcetrapib (no benefit) Other CETP inhibitors still in trials: anacetrapib, evacetrapib Fibrates ACCORD: benefit in subset with high TG/low HDL-C Event Rate (%) Placebo Niacin 47 Barter PJ, et al. N Engl J Med. 2007;357(21): Schwartz GG, et al. N Engl J Med. 2012; 367: ; N Engl J Med. 2008;358: ; The AIM-HIGH Investigators. N Engl J Med. 2011;365: ; HPS2- THRIVE Collaborative Group. Eur Heart J. 2013; 34: The HPS2-THRIVE Collaborative Group N Engl J Med 2014; 371: Nonfatal MI/ Nonfatal MI Stroke/TIA CHD Death Total follow-up, adjusted for baseline characteristics, p<0.05, 5-year rate Coronary Drug Project Research Group. JAMA 1975;231: Canner PL et al. J Am Coll Cardiol 1986;8: CV Surgery HPS2 THRIVE: No Improvement in Major Vascular Events Event Randomized allocation ERN/LRPT Placebo (12838) (12835) Risk ratio & 95% CI Non-fatal MI 402 (3.1%) 431 (3.4%) 0.93 ( ) 0.33 Coronary death 302 (2.4%) 291 (2.3%) 1.04 ( ) 0.63 Major coronary event 668 (5.2%) 694 (5.4%) 0.96 ( ) 0.51 p The HPS2-THRIVE Collaborative Group N Engl J Med 2014; 371: The short story is that NIACIN WAS INEFFECTIVE AND ASSOCIATED WITH SIGNIFICANT HARM. Ischaemic stroke 389 (3.0%) 415 (3.2%) 0.94 ( ) 0.37 Haemorrhagic stroke 114 (0.9%) 89 (0.7%) 1.28 ( ) 0.08 Any stroke 498 (3.9%) 499 (3.9%) 1.00 ( ) 0.56 Coronary revasc 591 (4.6%) 664 (5.2%) 0.89 ( ) 0.04 Non-coronary revasc 236 (1.8%) 258 (2.0%) 0.92 ( ) 0.33 Any revascularization 807 (6.3%) 897 (7.0%) 0.90 ( ) 0.03 Major vascular event 1696 (13.2%) 1758 (13.7%) 0.96 ( ) 0.29 European Heart Journal (2013) 34: ERN/LRPT better Placebo better
4 The HPS2-THRIVE Collaborative Group N Engl J Med 2014; 371: The short story is that NIACIN WAS INEFFECTIVE AND ASSOCIATED WITH SIGNIFICANT HARM. A more precise conclusion is that among participants with atherosclerotic vascular disease, the addition of extended-release niacin laropiprant to statin-based LDL cholesterol lowering therapy [simvastatin +/- ezetimibe, achieving avg LDLc 63 mg/dl and HDLc 44 mg/dl before randomization] did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events, particularly among the Chinese participants in the study. Niacin Trials: Questions Raised Why did these trials fail to show a difference? Coronary Drug Project showed benefit Atherosclerosis (angiographic and cimt) data previously suggested benefit Did we AIM too LOW with aggressive LDL-C therapy? If the LDL-C is <70 is there a benefit to raising HDL-C even though there is still increased residual risk? Who is the appropriate patient for niacin? Is there a specific subgroup that would benefit? Is HDL-C raising still a viable target of therapy? dal-outcomes: More Questions Raised Why did this trial fail to show a difference? No apparent off-target effects or harm as with torceptrapib Possibly due to lack of LDL benefit? Did we chose the wrong study population? High risk population on good evidence based regimen Are CETP inhibitors still worth investigating? Anaceptrapib/Evacetrapib in Phase 3 trials currently Is HDL-C raising still a viable target of therapy? Is HDL-C Still a Therapeutic Target? Low levels of HDL-C and apo AI remain strong predictors of increased risk of cardiovascular disease, even in patients with low LDL-C (but perhaps not very low LDL-C) LDL-C remains the primary target of lipid altering therapies NonHDL-C remains the secondary target HDL-C levels do not necessarily reflect HDL function Numerous HDL therapies still in clinical development that will help to answer many mechanistic questions Therapeutic Lifestyle Changes Weight management For every 7 lb weight loss, HDL-C levels increase by 1 mg/dl Increased physical activity Intensive aerobic exercise can modestly increase HDL-C levels by ~5% Smoking cessation Smoking lowers HDL-C levels 7% to 20% With cessation, HDL-C can return to normal after 30 to 60 days Dattilo AM, Kris-Etherton PM. Am J Clin Nutrition. 1992;56: Therapeutic Lifestyle Changes TLC Diet Low saturated fat (<7% of daily caloric intake) Low cholesterol (<200 mg/day) High fiber (10-25 g/day) Consider plant stanols/sterols (2 g/day) Very low fat diets will lower HDL-C Polyunsaturated fats may improve the antiinflammatory properties of HDL and should not necessarily be restricted (omega 3 and omega 6 FA) Alcohol intake raises HDL-C, but is not necessarily healthful Third Report of the NCEP Expert Panel. JAMA. 2001;285:
5 Kathy Plan (after cleared for elective surgery) Recommend TLC Repeat outpatient evaluation of all parameters in several months time Consider atherosclerosis imaging (eg CACS/cIMT) Consider statin therapy due to high lifetime risk Case 2: Melanie, a 28 y/o female Admitted with 1 wk of severe midepigastric abdominal pain/acute pancreatitis Medications: Oral contraceptive pill (OCP) SHx: Nonsmoker, rare alcohol FHx: Father with very high cholesterol PE: BP 120/80, BMI 26, rash on back and buttocks Fasting lipid profile (mg/dl) TC 210 HDL 38 TG 3540 LDL cannot be calculated, lipase is elevated Prevalence of Elevated Triglyceride Levels Hypertriglyceridemia Overall in the United States: 31% of adults have levels >150mg/dL (1.69 mmol/l) Mexican Americans: 35% Nonhispanic whites: 33% African Americans: 15.6% TG levels 200 mg/dl in 16.2% TG levels 500 mg/dl in 1.1% overall 9% in Mexican Americans aged 50 to 59 Primary / Genetic causes Lipoprotein Lipase, apolipoprotein C2 (LPL promotor) deficiency (chylomicrons or chylos + VLDL) Familial hypertriglyceridemia (VLDL) Familial combined hyperlipidemia (VLDL and LDL) Familial dysbetalipoproteinemia (Type III; remnants) Familial chylomicronemia syndrome (Type I) Miller M, et al. Circulation. 201;123: Secondary Causes of Hypertriglyceridemia Diseases/States Central/visceral adiposity, lipodystrophy DM/insulin resistance Sedentary lifestyle Endocrine d/o s (Cushings, hypothyroid) Kidney failure Liver disease HIV lipodystrophy Drugs/Diet Alcohol Diet Hormones Oral estrogen (BCP & ERT) Blood Pressure/Lipid Rx Retinoids Miscellaneous Management of Very Elevated TG No alcohol Weight loss of 5% to10% can lead to 20% reduction in TG levels Increased physical activity Dietary changes Need to remove almost all fat from diet until TG <1000 mg/dl Treat insulin resistance/deficiency/hyperglycemia Medications usually necessary for TG >1000 mg/dl Combination of lifestyle changes can help to lower TG by up to 50% Pejic R, et al., J Am Board Fam Med. 2006;19: Dattilo AM, Kris-Etherton PM. Am J Clin Nutrition. 1992;56: Miller M, et al. Circulation. 2011;123:
6 Effect of Pharmacologic Treatment on TG Drug % TG Reduction Fibrates IR Niacin Omega 3 FA ER Niacin Statins Ezetimibe 5-10 Dietary Changes to Lower TG/nonHDL-C Reduce simple carbohydrates (VLDL): <50% of calories; reduce/eliminate fat (chylomicrons) Higher fiber Minimal added sugar (<5%) and fructose (<50 g) No trans fats Reduce saturated fats to <5% In acute setting may need supplementation with medium chain triglycerides Consider Mediterranean type diet (higher in MUFAs, PUFAs) Miller M, et al. Circulation. 2011;123: Dattilo AM, Kris-Etherton PM. Am J Clin Nutrition. 1992;56: Miller M, et al. Circulation. 2011;123: Fish Oil and Omega 3 Fatty Acids Dosing for hypertriglyceridemia is 4 g daily (2 g bid) w/food Expected TG lowering of ~30% to 45% Formulations Prescription: indicated at as an adjunct to diet to reduce TG levels in adults with very high levels ( 500 mg/dl) Omega 3 acid ethyl esters [Lovaza, Omtryg, Epanova]: 1 g capsules (approx 465 mg EPA and approx 375 mg DHA or ~850 mg combined) Icosapent ethyl [Vascepa]: EPA only, 1 g capsules TG and CVD Risk Elevated TG often clusters with other cardiometabolic risk factors Not directly atherogenic, but represents an important biomarker of CVD risk because of its association with atherogenic remnant particles sdldl, VLDL remnants There is an increased risk for pancreatitis when fasting TG level exceeds 1000 mg/dl OTC: Standard concentrations are 120 mg DHA and 180 mg EPA Miller M, et al. Circulation. 2011;123: NCEP ATP III Triglyceride Management >500 mg/dl First lower TGs to prevent pancreatitis Very low fat diet (15% of calories from fat) Weight management and physical activity Identify and correct secondary causes: STOP OCP! Consider pharmacologic therapy: fibrate, omega 3 FA, (and/or nicotinic acid ) When TGs <500 mg/dl, turn to LDL/nonHDL-cholesterol lowering therapy > mg/dl Consider adding drug if needed to reach nonhdl-c goal Intensify therapy with LDL-c lowering drug, or Add nicotinic acid, Ω3-FA s or fibrate Melanie Diagnosis Type V hyperlipoproteinemia with pancreatitis Plan Stop OCP Nutrition counseling for TG lowering diet Fibrate and prescription fish oil for rapid TG lowering Exercise Complete abstinence from alcohol Third Report of the NCEP Expert Panel. JAMA. 2001;285:
7 Case 3: Gus, a 49 y/o AA Male Seen in follow-up for history of mixed dyslipidemia, hypertension, diabetes, fatty liver, and obesity Feels well, but concerned about recent weight gain of 20 lbs over the past 1 year Habits: Nonsmoker, occasional beer on weekend FHx: Mother and brother have diabetes, HTN PE: BP 140/84, BMI 34, otherwise unremarkable Gus Medications: aspirin, amlodipine, HCTZ, lisinopril, metformin, multivitamin, vitamin D, fish oil Previously prescribed a statin but he stopped taking six months ago after hearing a story on the news Fasting blood work (mg/dl): - TC 212 HDL 38 LDLC 138 apob TG 180 nonhdl glucose HbA1C 7.6% LFTs minimally elevated Factors Contributing to Cardiometabolic Risk Overweight/Obesity Genetics Age Insulin Resistance Insulin Resistance Syndrome Lipids BP Glucose Smoking, Physical Inactivity Brunzell JD, et al. JACC. 2008;51:1513. Hypertension Cardiovascular Risk Global Diabetes/CVD Risk Abnormal Lipid Metabolism LDL ApoB HDL Triglycerides Age;Race;Sex, Family History Inflammation, Hypercoagulation LDL Cholesterol Goals LDL Cholesterol (mg/dl) Non HDL Cholesterol (mg/dl) Apolipoprotein B (mg/dl) Highest Risk <70 <100 <80 High Risk <100 <130 <90 Highest risk: Known clinical CVD or diabetes and one other risk factor (smoking, hypertension, or family history of CVD) High risk: Diabetes without other risk factors 2013 ACC/AHA Cholesterol Guidelines Treat with moderate to high intensity statin NCEP ATP III Update, Grundy SM, et al. Circulation. 2004;110: ; ADA/ACCF Consensus. Brunzell JD, et al. JACC. 2008;51: ; ADA 2010 Guidelines. Diabetes Care. 2010;33:S4-10 Achieving LDL Cholesterol Goals Statin therapy is first line Statin therapy should be added, regardless of baseline lipid levels, for the highest risk diabetic patients, especially those >40 years Categorical indication for moderate or high intensity statin based upon the present ACC/AHA Guidelines Many large scale clinical trials show a reduction in CHD events with statins in patients with diabetes NCEP ATP III Update, Grundy SM, et al. Circulation. 2004;110: ; ADA 2010 Guidelines. Diabetes Care. 2010;33:S4-10. Gus Plan Counseled on diet/exercise; referred to nutritionist Started on atorvastatin 40 mg daily At four month follow-up: BP 132/80, 8 lb loss, BMI 33 Fasting blood work (mg/dl): - TC HDL 35 - LDL 87 - apob 90 - TG nonhdl 119 Glucose 141 HbA1C 7.3%
8 Options for Treating Residual Risk Residual LDL-C elevation Bile acid sequestrants Ezetimibe Niacin Modify statin therapy Atherogenic dyslipidemia Niacin Elevated triglycerides Fibrates Omega 3 fatty acids Take Home Points LDL-c/nonHDL-C; primary and secondary targets of lipid management Low HDL-C is strong CV risk marker but benefit from niacin added to statins/ezetimibe and use of CETP inhibitors have not demonstrated benefit in CV outcomes Rule out secondary cause of high TG Lower TG to <500 mg/dl to reduce risk of pancreatitis In highest risk DM patients, moderate to high intensity statin should be added
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationRecent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More information10/1/2008. Therapy? Disclosure Statement
What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationOmega-3 Fatty Acids. Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM
Omega-3 Fatty Acids Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM Chattanooga @a_l_bailey Disclosures None Objectives Describe omega-3 fatty acids Review the historic
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationControversies in Lipid Therapy: Is there any value in adjusting HDL levels?
Controversies in Lipid Therapy: Is there any value in adjusting HDL levels? Sergio Fazio, MD, PhD Cornelius Vanderbilt Chair of Cardiovascular Medicine and Professor of Medicine, Pathology, Immunology,
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationLipids: Translating Studies into Practice. WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH
Lipids: Translating Studies into Practice WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH Discussants: Bob Gleeson, MD Assistant Professor of Medicine, General Internal Medicine Medical
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationFinancial Disclosures
1 Lipids in Type 2 Diabetes July 20, 2013 Abhimanyu Garg, M.D. Professor of Internal Medicine Chief, Division of Nutrition and Metabolic Diseases Distinguished Chair in Human Nutrition Research UT Southwestern
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationPattern of lipid biomarkers and risk of cardiovascular disease
Pattern of lipid biomarkers and risk of cardiovascular disease Robert Clarke Clinical Trial Service Unit University of Oxford 9 January 2017 Biomarkers for dietary fats Blood lipids (LDL, HDL, triglycerides,
More informationLearning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?
Scott J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: It s a Matter of the Heart
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationAggressive Lipid Management for Diabetes
Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More information